Cargando…
Is flat dosing cost-effective? Re: ‘The same old story’: thoughts on authorised doses of anticancer drugs
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768569/ https://www.ncbi.nlm.nih.gov/pubmed/33488777 http://dx.doi.org/10.1177/1758835920974203 |
| _version_ | 1783629187082354688 |
|---|---|
| author | Farooq, Abdul R. O’Brien, Timothy O’Reilly, Seamus |
| author_facet | Farooq, Abdul R. O’Brien, Timothy O’Reilly, Seamus |
| author_sort | Farooq, Abdul R. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7768569 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-77685692021-01-21 Is flat dosing cost-effective? Re: ‘The same old story’: thoughts on authorised doses of anticancer drugs Farooq, Abdul R. O’Brien, Timothy O’Reilly, Seamus Ther Adv Med Oncol Letter to the Editor SAGE Publications 2020-12-25 /pmc/articles/PMC7768569/ /pubmed/33488777 http://dx.doi.org/10.1177/1758835920974203 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Letter to the Editor Farooq, Abdul R. O’Brien, Timothy O’Reilly, Seamus Is flat dosing cost-effective? Re: ‘The same old story’: thoughts on authorised doses of anticancer drugs |
| title | Is flat dosing cost-effective? Re: ‘The same old story’: thoughts on
authorised doses of anticancer drugs |
| title_full | Is flat dosing cost-effective? Re: ‘The same old story’: thoughts on
authorised doses of anticancer drugs |
| title_fullStr | Is flat dosing cost-effective? Re: ‘The same old story’: thoughts on
authorised doses of anticancer drugs |
| title_full_unstemmed | Is flat dosing cost-effective? Re: ‘The same old story’: thoughts on
authorised doses of anticancer drugs |
| title_short | Is flat dosing cost-effective? Re: ‘The same old story’: thoughts on
authorised doses of anticancer drugs |
| title_sort | is flat dosing cost-effective? re: ‘the same old story’: thoughts on
authorised doses of anticancer drugs |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768569/ https://www.ncbi.nlm.nih.gov/pubmed/33488777 http://dx.doi.org/10.1177/1758835920974203 |
| work_keys_str_mv | AT farooqabdulr isflatdosingcosteffectiverethesameoldstorythoughtsonauthoriseddosesofanticancerdrugs AT obrientimothy isflatdosingcosteffectiverethesameoldstorythoughtsonauthoriseddosesofanticancerdrugs AT oreillyseamus isflatdosingcosteffectiverethesameoldstorythoughtsonauthoriseddosesofanticancerdrugs |